Answers are grounded in this paper and cite their sources.
Background Judicial litigation against the Brazilian Unified Health System (SUS) is a major and poorly quantified channel of access to high-cost rheumatology drugs. We aimed to characterise the volume, financial exposure and regulatory profile of rheumatologic demands, and to test whether litigation tracks disease prevalence. Methods Cross-sectional analysis of all technical opinions issued by the National Council of Justice e-NatJus system (2019 to September 2026) with a primary ICD-10 code M05–M14, M30–M36, M45–M46 or L40.5. Opinions were deduplicated by case, and financial exposure was estimated from the maximum government price (PMVG) recorded in each opinion, annualised. Regulatory status was verified against ANVISA registration, CONITEC recommendation reports, Clinical Protocols (PCDT) and the ANS coverage list. Litigation intensity was expressed as opinions per 1,000 estimated prevalent cases. Results Of 5,923 opinions, 88.8% concerned medicines and 40.2% were favorable. Systemic lupus erythematosus (38.6%), systemic sclerosis (14.8%) and other connective tissue diseases or vasculitides (M30–M36, 75% combined) dominated; rheumatoid arthritis accounted for only 10.9%. Mycophenolate (1,114), rituximab (913), belimumab (862), nintedanib (216) and adalimumab (166) were the most demanded drugs. Three non-incorporated agents (belimumab, anifrolumab, nintedanib) represented 22.5% of drug demands, 28.8% of priced exposure and were favorable in only 25.8%. Among the 1,483 priced opinions, annualised exposure was BRL 120.1 million (USD 23.5 million), of which BRL 22.3 million corresponded to favorable opinions; extrapolation to all demands gives BRL 182–503 million per year. Favorable rates fell from 49.6% to 30.2% after the Supreme Court rulings of September 2024 (OR 2.27, p < 0.001) and were strongly associated with CONITEC recommendation (OR 5.76) and PCDT coverage (OR 2.03). Litigation intensity was inversely correlated with prevalence (Spearman rho = − 0.90, p = 0.037): 39.1 opinions per 1,000 cases in systemic sclerosis versus 0.66 in rheumatoid arthritis. Conclusions Rheumatologic litigation in Brazil is driven by rare connective tissue diseases and by a small set of non-incorporated biologics, not by the most prevalent conditions. Targeted health technology assessment with negotiated pricing for belimumab, anifrolumab and nintedanib, together with enforcement of existing protocols, could contain most of the projected exposure.
No takes yet. Share an insight, caveat, or question.
Korkes et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: